BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 34508238)

  • 1. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.
    Masoodi M; Gastaldelli A; Hyötyläinen T; Arretxe E; Alonso C; Gaggini M; Brosnan J; Anstee QM; Millet O; Ortiz P; Mato JM; Dufour JF; Orešič M
    Nat Rev Gastroenterol Hepatol; 2021 Dec; 18(12):835-856. PubMed ID: 34508238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
    Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
    J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in nonalcoholic fatty liver disease metabolomics.
    Kim HY
    Clin Mol Hepatol; 2021 Oct; 27(4):553-559. PubMed ID: 34098712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.
    Mato JM; Alonso C; Noureddin M; Lu SC
    World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
    Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
    Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.
    Dong S; Zhan ZY; Cao HY; Wu C; Bian YQ; Li JY; Cheng GH; Liu P; Sun MY
    World J Gastroenterol; 2017 Apr; 23(15):2771-2784. PubMed ID: 28487615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.
    Takahashi S; Luo Y; Ranjit S; Xie C; Libby AE; Orlicky DJ; Dvornikov A; Wang XX; Myakala K; Jones BA; Bhasin K; Wang D; McManaman JL; Krausz KW; Gratton E; Ir D; Robertson CE; Frank DN; Gonzalez FJ; Levi M
    J Biol Chem; 2020 Apr; 295(14):4733-4747. PubMed ID: 32075905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis.
    Zhu Q; Li H; Ao Z; Xu H; Luo J; Kaurich C; Yang R; Zhu PW; Chen SD; Wang XD; Tang LJ; Li G; Huang OY; Zheng MH; Li HP; Liu F
    J Nanobiotechnology; 2022 Jul; 20(1):349. PubMed ID: 35897102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.
    Gottlieb A; Canbay A
    Cells; 2019 Oct; 8(11):. PubMed ID: 31671697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of Metabolomics, Lipidomics, and Proteomics Reveals the Metabolic Characterization of Nonalcoholic Steatohepatitis.
    Zhang J; Yang Y; Wang Z; Zhang X; Zhang Y; Lin J; Du Y; Wang S; Si D; Bao J; Tian X
    J Proteome Res; 2023 Aug; 22(8):2577-2592. PubMed ID: 37403919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
    Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
    Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LC/MS-Based Untargeted Metabolomics Study in Women with Nonalcoholic Steatohepatitis Associated with Morbid Obesity.
    Bertran L; Capellades J; Abelló S; Durán-Bertran J; Aguilar C; Martinez S; Sabench F; Correig X; Yanes O; Auguet T; Richart C
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease stratification by liver lipidomics.
    Vvedenskaya O; Rose TD; Knittelfelder O; Palladini A; Wodke JAH; Schuhmann K; Ackerman JM; Wang Y; Has C; Brosch M; Thangapandi VR; Buch S; Züllig T; Hartler J; Köfeler HC; Röcken C; Coskun Ü; Klipp E; von Schoenfels W; Gross J; Schafmayer C; Hampe J; Pauling JK; Shevchenko A
    J Lipid Res; 2021; 62():100104. PubMed ID: 34384788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype.
    Erickson ML; Haus JM; Malin SK; Flask CA; McCullough AJ; Kirwan JP
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1197-1204. PubMed ID: 31371265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids.
    Gottlieb A; Bechmann L; Canbay A
    Ann Hepatol; 2018; 17(3):340-341. PubMed ID: 29735794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
    Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.